In the TME of ICC, CTLA-4 and PD-1/PD-L1 exhibit synergistic effects [43], which reveals that combination strategy of anti-CTLA-4 inhibitors and anti-PD-1/PD-L1 inhibitors may hold greater therapeutic potential [72]. This evidence concerns the gene CTLA4 and intrahepatic cholangiocarcinoma.